ME
Medico Remedies Ltd (MEDICO)
₹18.54
Mkt cap
₹152 Cr
P/E ratio
11.20
P/B
1.92
Div yield
0.00%
ROE
19.00%
ROCE
23.30%
EPS (TTM)
₹1.66
Book value
₹10
52W range
18–57
Sector
Healthcare
Price history
Previous close
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations [1]
NSE MEDICOBSE 540937
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−67.41% from high₹19
₹18+4.10% from low₹57
Current
₹18.54
Prev close
₹18.81
Day
−1.44%
Price performance
1D
−2.13%
1W
−0.16%
1M
−10.20%
3M
−56.24%
6M
−60.93%
1Y
−65.36%
YTD
−63.19%
Financials
Revenue, profit & margin
P/E ratio
11.2×
MEDICO is 66% below the sector median of 33.4×
MEDICO11.2×
Sector median33.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.36 | 29.77 | 41.32 | 30.80 | 39.35 | 39.49 | 41.30 | 38.25 | 52.64 | 58.68 | 56.81 | 69.40 | 73.97 | |
| YoY Sales growth | +4.70% | -23.37% | +47.62% | -2.13% | -7.11% | +32.65% | -0.05% | +24.19% | +33.77% | +48.59% | +37.55% | +81.44% | +40.52% | |
| Expenses | 39.29 | 27.04 | 36.67 | 27.98 | 36.94 | 36.38 | 34.64 | 35.43 | 49.91 | 54.35 | 49.66 | 66.10 | 70.81 | |
| Operating Profit | 3.07 | 2.73 | 4.65 | 2.82 | 2.41 | 3.11 | 6.66 | 2.82 | 2.73 | 4.33 | 7.15 | 3.30 | 3.16 | |
| OPM % | 7.25% | 9.17% | 11.25% | 9.16% | 6.12% | 7.88% | 16.13% | 7.37% | 5.19% | 7.38% | 12.59% | 4.76% | 4.27% | |
| Other Income | 0.96 | 0.27 | 0.58 | 0.29 | 0.68 | 1.43 | 0.29 | 0.66 | 1.72 | 0.68 | 2.87 | 1.17 | 1.31 | |
| Interest | 0.18 | 0.22 | 0.25 | 0.18 | 0.21 | 0.28 | 0.49 | 0.28 | 0.24 | 0.39 | 0.90 | 0.41 | 0.45 | |
| Depreciation | 0.71 | 0.72 | 0.74 | 0.75 | 0.75 | 0.76 | 0.77 | 0.77 | 0.73 | 0.79 | 0.80 | 0.72 | 0.75 | |
| Profit before tax | 3.14 | 2.06 | 4.24 | 2.18 | 2.13 | 3.50 | 5.69 | 2.43 | 3.48 | 3.83 | 8.32 | 3.34 | 3.27 | |
| Tax % | 22.61% | 30.10% | 26.89% | 27.06% | 27.23% | 25.14% | 23.90% | 25.51% | 25.86% | 25.07% | 29.69% | 24.55% | 27.22% | |
| Net Profit | 2.43 | 1.45 | 3.10 | 1.58 | 1.55 | 2.62 | 4.34 | 1.82 | 2.57 | 2.87 | 5.86 | 2.52 | 2.38 | |
| EPS in Rs | 0.29 | 0.17 | 0.37 | 0.19 | 0.19 | 0.32 | 0.52 | 0.22 | 0.31 | 0.35 | 0.71 | 0.30 | 0.29 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202661.38%Promoter
Promoters61.38%
FIIs0.60%0.52
DIIs0.00%
Public38.02%0.53
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,867.50 | 36.42 | 4,48,076 | 0.86% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,080.00 | 86.07 | 2,94,139 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,691.20 | 82.19 | 1,78,438 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,220.00 | 89.52 | 1,19,949 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,192.00 | 26.24 | 1,18,902 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,377.90 | 41.11 | 1,15,092 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,394.50 | 36.28 | 1,12,660 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Medico Remedies | ₹18.31 | 11.15 | 152 | 0.00% | 2 | −7.39% | 74 | +40.52% | 23.27% |
| Median: 160 Co. | ₹449.50 | 33.40 | 2,018 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports9
Concall transcripts2
Credit ratings4
Announcements5
Financial Results For Quarter Ended 30Th September, 2026. 9 Nov - Board approved Q2 FY2026-27 standalone results, appointed cost auditor, and issued postal ballot notice on 9 Nov 2026.Board Meeting Outcome for Intimation Under Regulation 30 (Read With Part A Of Schedule III) (LODR) Regulations, 2015 ("Listing Regulations') 9 Nov - Board approved Q2 FY2026-27 standalone results, appointed cost auditor for FY2026-27, and issued postal ballot notice.Board Meeting Intimation for Quarterly Financial Results 3 Nov - Board meeting on 9 Nov 2026 to approve Q2 FY2027 unaudited financial results.Clarification On Price Movement 29 Sep - Company clarifies share price movement is market-driven and no pending disclosures exist.Clarification sought from Medico Remedies Ltd 29 Sep - Exchange has sought clarification from Medico Remedies Ltd on September 29, 2026 with reference to significant movement in price, in order to ensure that investors …






